Access and support made easier
for you and your patients

The 3-step process for starting AFREZZA®
Patient access to AFREZZA begins with you
Prescribing the right dose of AFREZZA for maximum clinical benefits
Coverage in 3 easy steps:
  • Write the AFREZZA prescription
  • Submit the prescription
  • Complete the prior authorization (if required)
  • Schedule a certified AFREZZA trainer for patient training support and fax start sheet
  • Request additional patient resources
Submit the AFREZZA prescription to:
Sterling Specialty Pharmacy. CloudTop will determine cost and coverage and coordinate fulfillment for the patient.
Sterling Specialty Pharmacy
1312 Northland Drive Ste 500
Mendota Heights, MN 55120
NPI: 1225548480 | eScribe: 2433693
Phone: 844-4MANKND (844-462-6563)
Fax: 866-588-0371
Hours: 8:30 am - 6:30 pm ET
Enhance patient compliance and make care more accessible
Access patient support through AfrezzaAssist® and Patient Trainers
Phone (toll-free)
Patient Training & Support Hotline
Phone (direct line)
Monday – Friday, 8:30 AM
6:30 PM ET
Resources for you to get your patients started on AFREZZA
Sample Letter of Medical Necessity
Prior Authorization & Appeal Checklist
Intake Prescription Form
CloudTop Health Prior Authorization Request
Sample Letter of Appeal
© MannKind Corporation June, 2024. US-AFR-2506
Indications and Usage

Afrezza® (insulin human) Inhalation Powder is a rapid acting inhaled human insulin indicated to improve glycemic control in adult patients with diabetes mellitus.

Limitations of Use: Not recommended for the treatment of diabetic ketoacidosis, not recommended in patients who smoke or have recently stopped smoking.

Important Safety Information for Afrezza® (insulin human) Inhalation Powder

WARNING: RISK OF ACUTE BRONCHOSPASM IN PATIENTS WITH CHRONIC LUNG DISEASE. Acute bronchospasm has been observed in patients with asthma and COPD using AFREZZA. AFREZZA is contraindicated in patients with chronic lung disease such as asthma or COPD. Before initiating AFREZZA, perform a detailed medical history, physical examination, and spirometry (FEV1) to identify potential lung disease in all patients.